Fenretinide has been previously studied as a cancer preventive. Though it is less potent in reducing the risk of breast cancer recurrence than tamoxifen , another drug used to prevent and treat breast cancer, fenrentide has fewer side effects than tamoxifen. The main side effects of tamoxifen include hot flashes, irregular menstrual cycles, vaginal discharge or bleeding, and irritation of skin around the vagina. Currently, women with early stage breast cancer are four to five times as likely to develop cancer in the opposite breast than women who have not had breast cancer. In addition to reducing recurrent breast cancer risk in pre-menopausal women, fenretinide also decreased the risk of ovarian cancer .
Ovarian cancer is far less common than breast cancer but potentially more deadly.
Copyright 1997-2001 Imaginis Corporation. All rights reserved. Imaginis is a registered service mark of Imaginis Corporation, a health services company. All other trademarks and copyrights are property of their respective owners. Use of this online service is subject to the disclaimer and the terms and conditions contained herein.